Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTH | P32929 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aceturic Acid SCHEMBL5876 | 1.00 | — | — | |
| Aceturic Acid SCHEMBL2120015 | 0.97 | — | — | |
| Aceturic Acid SCHEMBL28156679 | 0.97 | — | — | |
| Aceturic Acid SCHEMBL27411062 | 0.97 | — | — | |
| Aceturic Acid SCHEMBL31614105 | 0.97 | — | — | |
| Aceturic Acid SCHEMBL10710298 | 0.97 | CTH (0.50) | CTHEGLN1ALDH1A1LMNAMAPT | |
| Aceturic Acid SCHEMBL9438413 | 0.97 | — | — | |
| Aceturic Acid SCHEMBL9130077 | 0.97 | — | — | |
| Aceturic Acid SCHEMBL31348252 | 0.97 | — | — | |
| Aceturic Acid SCHEMBL28850599 | 0.94 | CTH (0.48) | CTHEGLN1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1230209-B3 | STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | UCB PHARMA GMBH (DE) | 2011-10-05 | — | — | EP | claimed |
| US-10254272-B2 | Blood based biomarkers for diagnosing atherosclerotic coronary artery disease | Global Genomics Group, LLC (US) | 2019-04-09 | — | — | US | disclosed |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN THERAPEUTICS GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-8034797-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-7989654-B2 | High purity bases of 3,3-diphenylpropylamino monoesters | UCB PHARMA GMBH (DE) | 2011-08-02 | — | — | US | disclosed |
| US-7919117-B2 | Drug delivery of fesoterodine (fumarate) through the skin in a dosage ofo.r-20 mg per day and is provided in a polymer matrix for uniform release;contact adhesives; sel-adhesives; impermeable backing; flatness; geratrics;drug delivery; side effect reduction | UCB PHARMA GMBH (DE) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | CTH 2114/4885EGLN1 958/4885ALDH1A1 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.